We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Grin and Bayer it

19 July 2004 By Robert Cyran

The Swiss drugs group has sold its over the counter business at a premium. Other drugs firms will follow at these prices. For Roche, exiting at a strong price puts it in a good position to bolster its pipeline.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.